https://www.zacks.com/stock/news/2242244/bristol-myers-bmy-abecma-gets-odac-votes-for-label-expansion?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2242244
Mar 18, 2024 - Bristol Myers' (BMY) Abecma gets eight out of 11 votes from the FDA's ODAC for patients with triple-class exposed relapsed or refractory multiple myeloma in earlier lines of therapy.
zc:-85513231562097745
0
https://www.zacks.com/stock/news/2241446/bristol-myers-bmy-gets-fda-nod-for-breyanzi-s-label-expansion?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2241446
Mar 15, 2024 - Bristol Myers (BMY) obtains FDA approval for the label expansion of CAR T cell therapy, Breyanzi, for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
zc:-3282508303580057856
0
https://www.zacks.com/stock/news/2237621/bristol-myers-squibb-bmy-stock-dips-while-market-gains-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-2237621
Mar 07, 2024 - In the most recent trading session, Bristol Myers Squibb (BMY) closed at $53.28, indicating a -0.19% shift from the previous trading day.
zc:7287711034240964070
0
https://www.fool.com/investing/2024/02/17/is-it-too-late-to-buy-these-2-brilliant-passive-in/?source=iedfolrf0000001
Feb 17, 2024 - Patience will be rewarded with these stocks.
0
fool:4113932900354874855
0
https://www.zacks.com/stock/news/2225414/gilead-gild-to-buy-cbay-for-4-3b-add-pbc-drug-to-pipeline?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2225414
Feb 13, 2024 - Gilead (GILD) is all set to acquire CymaBay Therapeutics for $4.3 billion and strengthen its liver disease portfolio with the addition of seladelpar to its pipeline.
zc:-2849976509115006595
0
https://www.zacks.com/stock/news/2223529/biotech-stock-roundup-gild-amgn-bmy-s-q4-results-mor-up-on-nvs-deal-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2223529
Feb 08, 2024 - Earnings of Gilead (GILD) and Amgen (AMGN) are in focus in the biotech sector.
zc:3389672683287065650
0
https://www.zacks.com/stock/news/2223497/jazz-boosts-oncology-pipeline-with-kras-inhibitor-program?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2223497
Feb 08, 2024 - JAZZ inks a deal to acquire global rights to Redx Pharma's KRAS inhibitor program to strengthen its early-stage oncology pipeline.
zc:9071132893138823640
0
https://www.zacks.com/stock/news/2221922/bristol-myers-bmy-tsvt-car-t-cell-therapy-to-face-fda-s-odac?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2221922
Feb 06, 2024 - Bristol Myers (BMY) and its partner TSVT announce that the FDA's ODAC will meet in March to review data supporting the label expansion for CAR T-cell therapy.
zc:8567294693272462537
0
https://www.fool.com/earnings/call-transcripts/2024/02/02/bristol-myers-squibb-bmy-q4-2023-earnings-call-tra/?source=iedfolrf0000001
Feb 02, 2024 - BMY earnings call for the period ending December 31, 2023.
0
fool:-3658242652269932421
0
https://www.zacks.com/stock/news/2220369/bls-jobs-up-big-353k-3-7-unemployment?cid=CS-ZC-FT-ahead_of_wall_street-2220369
Feb 02, 2024 - 353K new jobs created for January are nearly double the 180K or so analysts were looking for.
zc:2410887625410279442
0